-transparent.png){kind=logo}
BACKGROUND The aim of treatment for HIV disease is prolonging survival and improvement in health-related quality of life. Ritonavir is a potent, orally bioavailable HIV protease inhibitor with demonstrated impact on surrogate endpoints, AIDS-defining disease, and mortality. OBJECTIVE To evaluate the effect of ritonavir combined with reverse transcriptase inhibitor therapy on patient functioning and well-being. METHODS An international, multicenter randomized placebo-controlled clinical trial of ritonavir was conducted in HIV-infected patients with CD4 cell counts < or = 100 x 10(6)/l. A total of 1090 patients were randomized to ritonavir and continued treatment with as many as two nucleoside agents (n=543) or placebo and continued treatment with as many as two nucleoside agents (n=547). Health-related quality of life was measured at baseline and after 3 and 6 months of treatment using the Medical Outcomes Study HIV Health Survey (MOS-HIV) and HIV-related symptoms scale. MOS-HIV contains 10 subscales and two summary scores (physical health and mental health). RESULTS The two treatment groups were comparable on baseline CD4 cell counts, demographic characteristics, and MOS-HIV and HIV symptom subscale scores. After 3 months, statistically significant differences (P < 0.03) favoring the ritonavir-treated patients were seen on the physical health summary, mental health summary, and general health perceptions, social function, mental health, and energy/fatigue subscales. After 6 months of ritonavir therapy, significant differences were observed on physical health and mental health summary scores (P < 0.001), and on measures of general health perceptions, physical function, role function, social function, cognitive function, mental health, health distress, energy/fatigue, and overall ratings of quality of life (P < 0.01). Ritonavir-treated patients reported fewer fever symptoms and neurologic symptoms than the placebo group after 6 months of treatment (P < 0.005). CONCLUSIONS Ritonavir therapy, combined with other antiretroviral treatments, significantly contributes to maintenance of functioning and well-being over at least 6 months in patients with advanced HIV disease.
C Cohen, and
D A Revicki, and
A Nabulsi, and
P W Sarocco, and
P Jiang
February 1998,
Lancet (London, England),
C Cohen, and
D A Revicki, and
A Nabulsi, and
P W Sarocco, and
P Jiang
February 2013,
Cancer,
C Cohen, and
D A Revicki, and
A Nabulsi, and
P W Sarocco, and
P Jiang
January 2009,
Journal of acquired immune deficiency syndromes (1999),
C Cohen, and
D A Revicki, and
A Nabulsi, and
P W Sarocco, and
P Jiang
January 2000,
AIDS (London, England),
C Cohen, and
D A Revicki, and
A Nabulsi, and
P W Sarocco, and
P Jiang
January 2004,
HIV clinical trials,
C Cohen, and
D A Revicki, and
A Nabulsi, and
P W Sarocco, and
P Jiang
August 2005,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
C Cohen, and
D A Revicki, and
A Nabulsi, and
P W Sarocco, and
P Jiang
January 2005,
Antiviral therapy,
C Cohen, and
D A Revicki, and
A Nabulsi, and
P W Sarocco, and
P Jiang
March 2002,
Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation,
C Cohen, and
D A Revicki, and
A Nabulsi, and
P W Sarocco, and
P Jiang
August 2009,
The Journal of antimicrobial chemotherapy,
C Cohen, and
D A Revicki, and
A Nabulsi, and
P W Sarocco, and
P Jiang
September 2003,
Journal of clinical epidemiology,
